Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELABEC: Ustekinumab in Behçet's disease (Phase 2, open-label)
2015-002190-37Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ustekinumab in Behçet's disease (BD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Treatment efficacy at week 24 and Safety and tolerability of ustekinumab. Started Jan 2016; status: completed.
02
Drugs
ustekinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2015-002190-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002190-37.